Arrayit Corporation (OTCBB: ARYC),
a life sciences and molecular diagnostics leader, announces today that
the company has sold a $166,000 NanoPrint™ LM60PRO Enterprise Level
Protein Edition Microarray Printer and accessories to a top research
center in Ontario, Canada. The Canadian researchers, featured widely in
the national and international media, will utilize Arrayit’s patented
technology to manufacture protein microarrays for exciting
interdisciplinary research applications. Arrayit protein microarrays are
powerful devices that contain miniaturized collections of intact
proteins, the molecules that comprise the building blocks of all living
organisms including humans, plants and animals. Protein microarrays
empower researchers with the tools needed to study the structure and
function of proteins, which are keys to understanding diverse
fundamental research topics including the mode of action of
pharmaceutical compounds, human disease progression, synthetic and stem
cell biology, ecology and population genetics.
Arrayit has been selling its patented microarray technology since 1997
to empower the proliferation of microarray technology worldwide.
Installed in more than 4,000 laboratories, Arrayit’s foundational
technology has been used to manufacture an estimated 100,000,000
microarray devices in university laboratories, biotechnology,
diagnostics and pharmaceutical companies, and government centers. The
company uses revenue from its life sciences research sales for continued
innovation, diagnostics research and development, and to keep pace with
market leaders Agilent, Illumina and Affymetrix. The company’s research
accounts also provide a continuous commercialization pipeline through
structured licensing and royalty agreements with laboratories wishing to
commercialize their important discoveries.
Arrayit recently completed a $1M equity capital raise and announced the
opening of its new and expanded Sunnyvale headquarters on January 1,
2014, which will feature CLIA and ISO laboratories certified with the
assistance of DOCRO, the clinical research organization leader from
Oxford, Connecticut. DOCRO is also assisting the company in 510(k)
submissions to the United States Food and Drug Administration for OvaDx®
and PDx™, the company’s pre-symptomatic diagnostic tests for ovarian
cancer and Parkinson’s Disease. Arrayit is adding key members to its
management and support teams to facilitate growth through organic
revenue increases, targeted M&A and the continued infusion of equity
capital.
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to
lead and empower the genetic, research, pharmaceutical, and diagnostic
communities through the discovery, development and manufacture of
proprietary life science technologies and consumables for disease
prevention, treatment and cure.
- Powerful Science for Life™
Visit http://arrayit.com/
for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as
"expect", "believe", and "should". Although we believe our expectations
are reasonable, our operations involve a number of risks and
uncertainties that are beyond our control, and these statements may turn
out not to be true. Risk factors associated with our business, including
some of the facts set forth herein, are detailed in the Company's Form
10-K for the fiscal year ended December 31, 2012 and in Form 10-Q for
the quarterly period ended September 30, 2013.
Copyright Business Wire 2013